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INTRODUCTION
Metabolic syndrome Characterised by four clinical elements:
these are Atherogenic dyslipidemia, insulin resistance (IR), central
Obesity, and high blood pressure.
The metabolic syndrome includes group of cardiac risk factors
that act simultaneously.
The persons with this syndrome who are worst prognosis
cardiovascular events
This is a is a group of components distressing about 20- 25% of
adults population in developed countries.
In India, prevalence is about 21% to 25% in adults. elevated BP
,Hyperglycemia and central obesity harmfully affected in heart both
physiologically and pathologically.
This disease and its components, such as hyper glycemia, raised
BP, Lipid profile abnomalities and central obesity are progressively more
common among our people due to inactive life style. These people most
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commonly manifested as Heart failure but patients had normal ejection
fraction (HFNEF) .
Persons with the metabolic syndrome have a high incidence of heart
failure HF. patients with metabolic syndrome  they are greater threat of
cardiac events than not associated this disease.
This study aimed to evaluate the association between
Leftventricular diastolic dysfunction and Metabolic syndrome. So far
there is minimal literature in our institute regarding the study of diastolic
dysfunction in subjects with metabolic syndrome.
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REVIEW OF LITERATURE
METABOLIC SYNDROME
HISTORY
First , DR. JEAN VAGUE, The Marseilles physician, in 1947,
found that upper body obesity influence to other metabolic complications
such as hyperglycemia, hyperlipidemia, gout and stone(1,2,3)
 HALLER, describe The relations of central obesity, diabetes,
dyslipedemia, Elevated uric acid level, and fatty infiltration. These
factors are the Synergitic property of risk factors on lipid
accumulation in vessels. He first Describe the term METABOLIC
SYNDROME (5)
 SINGER illustrate the relationships  between the cental obesity,
hyper uricemia and hyperglycemia and elevated BP with
dyslipidemia in the same year[6]
 Gerald B. Phillips in 1977-78 explain the theory that risk factors
for MI to form joint risk factors such as hyper glycemia, elevated
insulin levels , hypercholesterolemia , hyper triglyceridemia and
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hypertension which are associated with elderly people and over
weight patients.
He told that linking factor which lead to prevent cardio vascular
disease which is sex hormones.[7][8]
 Famous professor Gerald M reaven  gives lecture regarding
metabolic syndrome , He described mainly associated with insulin
resistance and  named constellation of abnormalities syndrome X.
After that abdominal obesity included further criteria formed by WHO
[1999], EGIR [1999], NACP-ATPIII [2001], AACE [2004], IDF[2006].
OTHER NAMES
 Dys metabolic syndrome
 The Deadly Quartet
 Insulin resistance syndrome
 Obesity syndrome
 Syndrome X
 Obesity mainly abdominal
 Lipid profile abnormalities
 Increased BP
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 Blood glucose abnormalities such as IR, IGT
 state of Pro inflammation
 Abnormalities of Thrombotic mechanism
These components of the metabolic syndrome, according to Adult
treatment panel III may divides underlying, major, and emerging risk
factors for CVD
 Increased weight
 sedentary life style and
 high fat food
 smokers
 Elevated BP
 High  LDL level
 less HDL level
 Any h/o of premature coronary artery disease (CAD) in the family
and
 Increasing age
19
Emerging risk factors
 High TGL
 High LDL particles,
 Resistance to insulin,
(11)
Figure (1) shows components of metabolic syndrome
Abdominal obesity
Abdominal obesity is well connected with the metabolic syndrome
complications. It is clinically obtainable as increased waist circumference
20
Atherogenic dys lipidemia
It diagnosed by lipid profile abnormalities such as elevated TGL
level and less HDL  level.
In comprehensive investigation of lipids ,the results commonly
reveals Other abnormalities of lipoprotein, such as raised lipoproteins
remnants, high apolipoprotein B level.
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Elevated blood pressure
Elevated BP frequently connections with central obesity and
frequently occurs who are resistant to insulin.
Insulin resistance {IR}
It is most commonly associates with the this syndrome. Insulin
resistance with other risk factors are well correlates with cardio vascular
events.
INSULIN RESISTANCE - RELATED CONDITIONS
(11)
Figure (2) shows insulin resistance associated conditions
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Prothrombotic state
It is categorized by  elevated fibrinogen and ( PAI- 1)plasminogen
activator inhibitor which well connected with this syndrome.
METABOLIC SYNDROME - PATHOGENESIS
It has three etiological categories:
a. insulin resistance
b. Central obesity and lipid storage abnormality;
c. constellation of independent factors
Other risk factors are
o Increasing age
o Active inflammatory state
&
o Endocrine  abnormalities
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PATHOPHYSIOLOGY OF METABOLIC SYNDROME
Figure( 3) shows Pathophysiology of the metabolic syndrome
OBESITY AND ABNORMAL BODY FAT DISTRIBUTION
Central obesity as primarily accountable for the rising occurrence
of this syndrome.
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Excess releases of substances from adipose tissue which
exaggerate these risk factors. These are PAI-1, adiponectin. non esterified
fatty acids (NEFA),and cytokines.
Insulin Resistance
In pathogenesis of metabolic syndrome insulin resistance play a
mojor  role other then any factors (12,13).
Insulin resistance elevates with raising body fat mass, yet give
widerange of insulin sensitivities .(14).
When the Persons with obesity had body mass index    more than
30 have Elevated post prandial insulin  level and low sensitivity of
insulin (15).
Variation of the insulin sensitivity occurs even within the obese
population .(14)
Asians population insulin resistance occurs still among BMI
About 25 and provide increase to a  high incidence of cardio vascular
disease And hyperglycemia.
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Primary insulin resistance which is manifested in south asians , as
eight gain enhance the insulin resistance and metabolic syndrome Even
in pts with primary insulin resistance(16)
INDEPENDENT FACTORS FOR METABOLIC SYNDROME
Factors Contributing to Insulin Resistance
Genetics
&
Aging
Acquired
Acquired:
• Central obesity
• Sedentary
lifestyle
•High fat diet
•Medications
(17)
Figure (4)shows  factors contributing to insulin resistance
26
Other risk Factors
All levels of pathogenesis affected by Advancing age so,
occurrence of the metabolic syndrome rises with elderly people (18).
Many endocrine disorders had directly related to abnormality
of lipid accumulations and indirectly related to this syndrome.
27
DIAGNOSIS
TABLE- 1 - ATP III CRITERIA
Factor Definite Level
Central obesity  ( waist
circumference)
Male
Female
More than 102 cm (> 40 inches)
More than 88 cm  (>35 inches)
TGL More than 150mg/dl
HDL cholesterol
male
female
Less than 40 mg/dL
Less than50 mg/Dl
Blood pressure more than130 mmHg systolic BP
more than 85 mmHg diastolic BP
FBS More than110 mg / dL
Diagnosis of metabolic syndrome by fulfilment of 3 out of 5
criteria.
Clinical adverse effects of metabolic syndrome was identified as
Cornary heart disease and cerebrovascular disease .
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Recently cut off points would be lowered FBS more than 100
mg/dL, can be considered which persons have impaired fasting glucose
or taking treatmentof hyper glycemia.(19).
TABLE -2 - WHO CRITERIA
any one of the subsequent criteria:
 Known diabetes on treatment
 IFG
 IGT
 Normal FBS  level
Plus any of the two in subsequent criteria:
 Any  medication for high BP and /or rised BP more than 140
mmHg in systolic or diastolic BP more than 90 mm Hg
 TGL LEVEL more than150 mg/dL
 High density lipid  level  < 35 mg / dL -male or <39 mg / dL –
female
 BMI more than >30 and /or ratio between waist and hip more than
.9 in male, more than .85 in female
 Albumin level in the urine more than 20 g/min or ratio between
albumin and Creatinine in urine more than 30 mg/g (20, 21)
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In 1998, WHO  define   functional classification of hyperglycemia
that included a implementation of criteria  of this  syndrome(20)
BMI  or  increase ratio  between waist and hip  was used in its
place of waist  Circumference alone, and micro albuminuria  used  a part
of metabolic syndrome in this criteria.
30
AACE (22 ) propose a another criteria for Metabolic syndrome
TABLE -3
RISK FACTOR DEFINE  LEVEL
Body weight BMI more than 25
Raised TGL >150 mg / dL
less HDL
Male
Female
< 40mg / dl
< 50mg / dl
Raised BP More than 130 in systolic  > 85
mm Hg in diastolic
Two hour glucose test More than 140 mg/dL
FBS 110 TO 126 mg/Dl
Other risk factors
Family h/o of hyperglycemia, HT,
or CVD, PCOD, Sedentary lifestyle,
increasing age
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INTERNATIONAL DIABETES FEDERATION, [2005]
TABLE - 4
 Central obesity
WC more than 94 cm for male
and more than 80 cm for female
add any of the 2 subsequent criteria
 High Density Lipid :
Male - < 40 mg/dL
Female - < 50 mg/dL
taken drugs for this type of dyslipidemia
 TGL LEVEL :
More than150 mg / dl or taken any drugs for this type of
Dyslipedemia
 BP
BP more than 130 in systolic and or diastolic BP  more than85 mm
Hg, taking  any drugs  HT
 FPG:
More than 100 mg/dL or known case of T2DM
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METABOLIC SYNDROME AS A RISK CONDITION
MS with more risk factors carries a greater risk of adverse events
in comparison to that with a single risk factor.
CARIO VASCULAR EVENTS
Persons with this disorder  are higher risk for Coronary heart
disease(23).
Various  studies shows Including the standard Framingham
algorithm(24) generally  most of the risk factors related with this
syndrome re capture by elderly people, hypertension, lipid abnormalities,
hyperglycemia, and less HDL level.
DIABETES AS A PREDICTOR OF CVD
Oxford investigators study find that (25) measure of glycaemia
and duration of diabetes that predict the cardio vascular events.
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THERAPEUTIC APPLICATIONS
OBESITY AND LIPID DISTRIBUTION
Obesity is the the chief target of intervention for metabolic
syndrome suggested by ATBIII.
Obesity  approached by weight reduction by increased physical
exercise and smoking cessation.
FIGURE -5 Shows treatment of metabolic syndrome
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INSULIN RESISTANCE
Metformin can be used to decrease insulin resistance of reduce the
risk for Cardio vascular events in in patients with this syndrome.
SPECIFIC RISK FACTORS
Atherogenic Dyslipidemia;
Statins and fibrates can be useful for lowering of lipids and also
reduce all apolipoprotein B–containing lipoproteins.(26)
HYPERTENSION
It is treated with lifestyle modifications and weight reduction that
leads to reduce blood pressure by use of antihypertensive drugs.
Prothrombotic State
Anti platelet drugs can be useful for this type of  risk factor
associated with this syndrome. Can be used with small dose of aspirin
decrease the cardiovascular events markedly.
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Hyperglycemia
Hyperglycemia can be treated  with insulin sensitizers and life
style modificatios,and physical exercise.
Pro inflammatory State
Most of the hypo lipedemic agents will decrease C –Reactive
Protein levels, which leads to anti-inflammatory action.
36
LEFT VENTRICULAR DIASTOLIC
DYSFUCTION
For a long time, all are presumed systolic dysfunction to be a
primary cause of cardiac failure. But various studies and methods shows
abnormality in diastolic function also in can precipitate cardiac failure
and determined prognosis of the patient.
Diastolic dysfunction due to abnormal relaxation, abnormal
refilling, and distensiablity.
There may be considerable overlap the signs and symptoms of both
diastolic and systolic heart failure.
PATHO PHYSIOLOGY
Ventricular diastole has four phases
 Iso volumetric relaxation:
 Period from closure of valve of the aorta to the opening of the
valve of the mitral area
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 Phase of the  early rapid ﬁlling :
 In this phase gradient of the trans mitral pressure responsible
for LV ﬁlling;
Figure 6 - shows relationship of pressure and volume of left ventricle in
the period of diastole
 Diastasis phase:
It is the period of less blood flow in middle phase of the diastole;
38
 phase of late period of rapid ﬁlling:
This is  due to contraction of the atrium.
Figure -7 shows left ventricular heamodynamics
39
PATHO PHYSIOLOGY
Table- 5
PATHO-
PHYSIOLOGY
All these factors can leads to diastolic heart failure and diastolic
dysfuction
40
Figure - 8 shows graphical representation of Pressure–volume for the
Left Ventricle Period of diastole. (27)
41
Table -6 Causes of Diastolic Dysfunction  and Heart Failure
Common causes
 Cardiac ischemia
 Elevated BP
 Increasing age
 Central Obesity
 Aortic valve stenosi
Uncommon causes
Disorders of myocardium
 Diseases of myocardium
 Infiltrative disease  such as amyloidosis, sarcoidosis, fatty
 infiltration of the heart
 Non infiltrative diseases such as idiopathic and hypertrophic
cardio myopathy)
 Endo myocardial diseases
 Hyper eosinophilic syndrome
 Glycogen storage disorders
 Hemochromatosis
disorders of Pericardium
 Constrictive pericarditis
 Pericardial effusion
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CLINICAL FEATURES:
Generally symptomless patient is more common than
symptomatic pts who had diastolic dysfunction. When symptoms are
there, DHF are very difficult to differentiate from those of Systolic heart
failure .
Symptoms are
Less exercise competence;
Neuro Humoral activation with water retention;
PND, Orthopnoea.
Exercise intolerance is often an early symptoms (28)
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Table -7- SIGNS AND SYMPTOMS IN SYSTOLIC AND
DIASTOLIC HEART  FAILURE (29,30)
DHF
(EF –more
than50%)
SHF
(EF -less than50%)
CLINICAL SYMPTOMS
Exertional  Dyspnoea
PND
Orthopnoea
85
55
60
96
50
73
SIGNS
JVP elevation
crepts
apical impulse displacement
S3
S4
Liver enlargement
Oedema
35
72
50
45
45
15
30
46
70
60
65
66
16
40
X-RAY - CHEST
Cardiac enlargement
Pulmonary hypertension
90
75
96
80
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DIAGNOSIS
Diagnosis of diastolic dysfunction may be difficult  because
history, clinical symptoms and signs are same as systolic dysfunction.
Various investigation may be differentiate the DHF from SHF.
Among those investigations echo cardiogram play a major role in the
diagnosis of the diastolic dysfunction.
Diastolic heart failure diagnosed by
 Normal left ventricular systolic function
 Any abnormal myocardial relaxation
 Abnormal diastolic filling pressures at rest
According to American society of cardiology all above criteria
should be fulfilled.
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METHODS OF DIAGNOSIS
o M MODE ECHO CARDIOGRAM
o DOPPLER ECHO CARDIOGRAM
o TISSUE DOPPLER
o PULMONARY FLOW PATTERN
ECHO CARDIOGRAM
It is the Most accessible and acceptable non invasive investigation
of choice
 It measures mitral inflow  velocity it is the earliest marker of
left ventricular filling abnormalities
DIASTOLIC DYSFUNCTION can be assessed In the form of
E wave - due to early diastolic filling
A wave - filling due to contraction of the atrium in late stage of
Diastole
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Figure- 9 shows pictorial representation of diastolic trans mitral
doppler assesment
DT – Deceleration time
IVRT- isovolumic relaxation time
E/A RATIO
According to these value diastolic dysfunction can be graded.
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PULMONARY VENOUS FLOW:
It measure in Right upper pulmonary vein from apical 4 chamber
view.
.
Figure -10 shows transmitral Doppler flow pattern
A- Normal
B- Pseudo normalization or stage 2 diastolic dysfunction
C- C-advancing disease (58)
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TABLE- 8:CRITERIA FOR DIASTOLIC HEART FAILURE (59).
Clinical features of HF Effort dyspnoea, orthopnoea, III-IV tones,
Pulmonary rales
Normal or diminished
LV systolic function
EF more than 45 %  LVIDDi  more than 3.2 cm
abnormality Left
Ventricular distension
/complaince
IVRT - less than30 years - more than 92 ms,
30 to 50 years - more than 100 ms,
More than 50 yrs - more than 105 m
secs
EA ratio less than one + DecTime – more than
220 msecs + S/D less than 1.5 in below 50 yrs
E/A - less than 0.5 + DT more than 280 ms +
S/D more than 2.5 above 50 yrs
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TREATMENT OF DIASTOLIC HEART FAILURE:
INITIAL TREATMENT:
Pt first treated with supportive therapy such as O2 therapy and
according to the underlying cause such as ischemia, constrictive
pericartitis, atrial fibrillation Main goal To diminish the pulmonary
congestion by Diuretics can be used with cautiosly.
Because it can leads to hypo tension related complication.
If there is no respiratory compromise morphine can be given.
If blood pressure normal nitroglycerin can be given.
HEART RATE REDUCTION:
It is can be achieved by the use of Beta –blockers
And Calcium channel blockers (CCB).
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LIFE LONG TREATMENT
Long term treatment depend upon the underlying disorder
Such as life long anti failure treatment such as ACE inhibitor and
spiranolactone and CABG.
Non-pharmacological
Dynamic and iso tonic physical activity can be useful..(33)
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LEFT VENTRICULAR DYSFUNCTION IN METABOLIC
SYNDROME
 Obesity and hypertension are independent factors  of impaired left
ventricular dysfunction(34,35,36)
 Correlation of numbers of risk factors  of this syndrome and
presence of grading of left ventricular diastolic dysfunction is
well documented(37,38,39)
 Obesity prevalence is increasing world wide and  makes important
risk factor for morbidity and mortality of cardio vascular disease
 Central obesity contribute the structural and functional
abnormalities directed by disproportionate increase of cardiac
output mediated by adrenergic stimulation and indirectly by
increasing left ventricular mass(40,41,42)
 In PROCAM STUDY  (Prospective cardiovascular munstar study)
shows
 Who had hypertensive only or diabetic only had 2.5 times
greater risk of  cardio vascular events
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 If pts had both hypertension and diabetes 8 fold high risk of
cardiac events
 If pts had both hypertension and diabetes  and lipid profile
abnormalities  who had 20 fold greater risk of cardiac
events.(43)
 Diabetes has independent unfavourable cardiac events which
may contribute to cardiovascular morbidity in hyperglycaemia
patients [44].
 There is a relation between the period of hyperglycemias’ and the
stages of Left Ventricular diastolic dysfunction [45].
 Masugata H et al (46) study shows person  with this syndrome
can have left ventricular diastolic dysfunction even if pt have
normal cardiac fucntion
 Hui-pinget al(47)in their study shows pts with these syndrome
even if they have normal Ejection Fraction , Left Ventricular
systolic and diastolic functions were impaired.
 Miyazato et al (48) FPG is a responsive indicator for Left
Ventricular diastolic dysfunction in non diabetic pts and small raise
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in blood glucose levels is related with abnormality in diastolic
dysfunction.
 Hwang et a1(49) in their study pts with insulin resistance
commonly detected unusual left ventricular morphology and
diastolic dysfunction.
 This syndrome with IR are associated with unusual Left
Ventricular diastolic dysfunction and structure that is not related to
tha age,sex, BP, and Blood sugar level.
 Ahn et al (50 ) found that thecomponents of Metabolic Syndrome
cluster was powerfully correlated with diastolic dysfunction.
 Barbosa et al(51) over weight is well correlated with ventricular
dysfunction. Over weight is  remain a important  predictor of
diastolic dysfunction
 Chopra et al(53) in this study if Metabolic syndrome found that,
impaired relaxation grade1 DD was highly prevalent .
 Bilal  et al(54) stated describes, females had the evidence of early
ventricular dysfunction. In isolated metabolic syndrome.
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 Evrengul et al(55) in their study found that,   peak A velocity (p
< 0.028) were significantly higher .
 Stijntje  et al (56) in this study found that, irrespective of blood
pressure ,pts with this syndrome shows decrease LV diastolic
function .
 Khan et al (57) in this study found that  positive correlation
components of metabolic syndrome and parameters assesed by
echo.
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STUDY PROTOCOL
AIMS AND OBJECTIVES:
1) To assess left ventricular function in metabolic     syndrome
2) To grade the diastolic dysfunction and clinical    outcome
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MATERIALS AND METHODS
STUDY SITE
Department of General Medicine, Government Stanley Medical
college and Hospital, Chennai.
COLLABORATING DEPARTMENTS
 Department of Cardiology
 Department of Medical Biochemistry
STUDY DESIGN
Longitudinal study
STUDY PERIOD
June 2012 to November 2012
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SELECTION OF STUDY POPULATION
INCLUSION CRITERIA
Patients meeting criteria for metabolic syndrome without
co morbid illness
EXCLUSION CRITERIA
 Cushing syndrome
 Hypothyroidism
 Anasarca
 Known heart disease patients
 Gout
 Polycystic ovarian disease
EXAMINATION
 height
 weight
 waist circumference
 pulse rate
 blood pressure
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INVESTIGATIONS DONE
 Complete blood count
 Blood sugar – Random, fasting and post prandial
 Blood urea
 Serum creatinine
 Serum uric acid
 Serum electrolytes
 Urine routine analysis
 Lipid profile
 Thyroid function test
 USG abdomen
 ECG
 ECHO
SAMPLE SIZE
 Using the above mentioned criteria 50 subjects were recruited
SAMPLING METHOD
 Convenience sampling method was adopted
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STUDY PROTOCOL
Figure (11) shows study protocol
Statistical analysis
Data entry in MS Excel 2010
left ventricular diastolic function assesed by measuring E(early filling
wave) and A(wave due to atrial contraction) velocity and myocardial
relaxation.  grading I to IV done
Results of investigation noted
Dphysical and systemic examination
Subjects recruited as per inclusion and exclusion criteria
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ECHOCARDIOGRAPHY
 Done by a qualified cardiologist
 Transthoracic echocardiographic examination done on all subjects
in left lateral position
 Two dimensional and M-mode echocardiography was performed
on using 3.5 MHz transducer
 Ejection fraction calculated measuring internal diameter of left
ventricle(LV) at the end  diastole (LVIDd) and at the end systole
(LVIDs) sing the Penn convention method
 Two dimensional and two dimensional guided M-mode
echocardiogram and pulsed Doppler trans mitral and pulmonary
venous flow velocity curves were obtained
 The trans mitral flow velocity curves were recorded with sample
volume at the mitral tips, and the pulmonary venous flow velocity
curves were recorded with the sample volume 1 to 2 cm into the
right superior pulmonary vein using the guidance of color flow
Doppler imaging with the transducer placed at the cardiac apex
 The averaged values of all echo cardio graphic parameters of at
least 3 consecutive beats were used for the analysis
 Doppler velocity curves were recorded at a horizontal sweep speed
of 100mm/s
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 Left ventricular diastolic dysfunction was assessed by evaluating
the mitral in flow velocity curves(MIVC)
Normal E/A ratio is defined as E/A ratio ≥ an age and sex adjusted
mean value – 2SD and pulmonary venous A duration – mitral A
duration (∆d) ≥0
 E deceleration time [E(dt)] and pulmonary venous A wave
amplitude(P va) were other values calculated
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Table – (9)  Grades of diastolic dysfunction – ECHO
Diastolic
Dysfunction
Stages
E/A
Ratio
(Cm/s)
DT
(ms)
IVRT
( ms)
M-Mode
(Vp cm/s)
Tissue
Em
(cm/s)
Normal Pattern
>1 160-210 70- 90 >45 >8
I -Stage Of
Delayed
Relaxation
<1 >220 >95 <45 <8
II)  Pseudonormal
Pattern 1-2 150-200 60 – 95 <45 <8
Iii. Restrictive
Filling Stage >2 <150 <60 <45 <8
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STATISTICAL ANALYSIS
Statistical analysis was done using
 Percentages
 Mean values
 Standard deviation
 Standard error
 Chi square test
 T-test unpaired
Level of significance used is 0.05 for the corresponding degree of
freedom to draw the inference. A p value <0.05 was considered
statistically significant.
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RESULTS
A longitudinal study consisting of 50 metabolic syndrome
outpatients and inpatients attending the Department of Medicine,
Government Stanley medical college hospital, Chennai was undertaken to
assess the left ventricular diastolic function.
Gender
Chart 1
A total of 50 patients diagnosed with metabolic disorder were included in the study.
Males constituted 28 %(n=56) of the sample population and females constituted
44%(n=22) (Chart 1)
22, 44%
28, 56%
Gender Distribution
Males
Females
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Age distribution
Chart 2
Most of the patients were clustered in the 41-45 years age group (n=14, 28%)
followed by the 51-55 years age group (n=11, 22%) (Chart 2).  Minimum age was 38
years and the maximum age is 57 years. The mean age was 46.96 years with standard
deviation 6.61.
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Age Distribution
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Blood pressure
Table 10
Blood pressure Number(n) Mean StandardDeviation(SD)
SBP in mm Hg 50 133.08 10.69
DBP in mm Hg 50 85.44 4.68
The mean systolic blood pressure and diastolic blood pressure are 133.08±10.96 and
85.44±4.68 respectively.
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Waist measurement
Table 11
Waist
measurement Number(n) Mean
Standard
Deviation(SD)
Men 28 96.14 5.42
Women 22 95 6.36
The mean waist measurement is 96.14 ±5.42 in males and 95 ±6.36 in females
respectively.
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Blood sugar
Table 12
Blood sugar Number(n) Mean StandardDeviation(SD)
FBS mg/ml 50 113.14 10.94
The mean fasting blood sugar levels among the study subjects is 113.14 ±10.94.
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Serum Triglycerides
Table 13
Serum
Triglycerides Number(n) Mean
Standard
Deviation(SD)
TGL  mg/ml 50 161.78 14.04
The mean triglyceride levels among the study subjects are 161.78 ±14.04.
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High density lipoproteins
Table 14
High density
lipoproteins Number(n) Mean
Standard
Deviation(SD)
Males 28 43.78 5.29
Females 22 48.27 6.19
The mean high density lipoprotein levels among the study subjects are 48.27 ± 6.19.
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ECHO parameters
E/A ratio
Table 15 (A)
E/A
Number Mean Standarddeviation Maximum Minimum
50 0.74 0.13 0.46 1.01
The E/A ratio ranged from 0.46 to 1.01 in cases with a mean of 0.74 ± 0.13.
Table15 (B)
E/A ratio Number Percentage
< 1.0 47 94%
>1.0 3 6%
Total 50 100%
94% had abnormal diastolic function as defined by E/A ratio. 3% had normal diastolic
function.
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Deceleration time of E (DT of E)
Table 16 (A)
DT
(msec)
Number Mean StandardDeviation(SD) Minimum Maximum
50 242.86 12.87 212 265
The Deceleration time of E ranged from 212 to 265 in subjects with a mean of 242.86
± 12.87.
Table 16(B)
DT
(msec) Number Percentage
150 -200 msec 3 6%
160-210 msec 31 62%
>220  msec 16 32%
Total 50 100%
Three patients had DT values between 150-200 msec and 31 patients were present
between 160-210 msec and 16 had values greater than 220 msec.
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Isovolumetric relaxation time
Table 17(A)
IVRT
(msec)
Number Mean StandardDeviation(SD) Minimum Maximum
50 92.2 17.62 57 123
In the present study, the mean ad SD of IVRT group was 92.2 ± 17.62 msec, with a
minimum value of 57 msec and maximum valueof 123 msec.
Table 17 (B)
IVRT
(msec) Number Percentage
<60 msec 3 6%
70-90 msec 31 62%
>95  msec 16 32%
Total 50 100%
Three patients had < 60 msec and 31 had between 70-90 msec and 16 had > 95 msec.
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Left ventricular diastolic dysfunction in study subjects
Table 18
Cardiac Dysfunction Number Percentage
Normal 24 48
Impaired Relaxation 18 36
Pseudonormal 8 16
Total 50 100
As shown in table   and chart  , out of 50 subjects,
 24(48%) had nrmal diastolic function
 18(36%) had impaired relaxation
 8(16%) had pseudonormal pattern
 Thus 26(52%) subjects had diastolic dysfunction
Chart 3
8, 16%
18, 36%
Left Ventricular Diastolic Dysfunction
24, 48% Normal
Pseudo Normal
Impaired Relaxation
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Mean values of Diastolic dysfunction parameters
Table 19
ECHO
Parameters
Left Ventricular Diastolic Dysfunction
Normal ImpairedRelaxation Pseudonormal
E/A ratio 1.08 0.82 1.12
DT 166.33 157.83 186.75
IVRT 90.08 86.56 96.25
The table above shows the following
E/A ratio
 E/A ratio is 1.08 in the normal group
 0.82 is the reading in the impaired relaxation group
 Pseudonormal group has a value of 1.12
DT
 Deceleration time in the normal group is 166.33 ms
 In the impaired relaxation group it is 157.83 ms
 186.75 ms is the value in the Pseud normal group
IVRT
 Isovolumetric relaxation time is 90.08 ms in the normal group
 The value in the impaired relaxation group is 86.56 ms
 In the Pseudonormal group the value is 96.25 ms
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Mean values of study parameters in relation to left ventricular
diastolic dysfunction
Table 20
Study
parameters
Left Ventricular Diastolic Dysfunction
P value
Normal ImpairedRelaxation Peudonormal
Age in years 46.96 52.22 47.11 0.086
Systolic BP mm
Hg 133.08 139.56 146.11 0.969
Diastolic BP
mm Hg 85.44 88.57 90.32 0.809
Waist (male)
cms
96.14 95.32 95.98 0.442
Waist (female)
cms
95 94.63 94.11 0.454
FBS mg/dl 113.14 128.36 131.75 0.300
TGL mg/dl 161.78 131.11 122.38 0.220
HDL mg/dl 43.78 42.96 41.00 0.611
77
Correlation of age with left ventricular diastolic dysfunction
Chart 4
As depicted in table 13   and chart 4 mean age in the normal group is 46.96 years, in
impaired relaxation group it is 52.22 years and in the pseudonormal group is 47.11
years. Though the age range was higher in impaired relaxation group, it was not
statistically significant (p=0.086).
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Correlation of systolic BP with left ventricular diastolic dysfunction
Chart 5
As depicted in table 13   and chart 5   mean systolic BP in the normal group is 133.08
mm Hg, in impaired relaxation group it is 139.56 mm Hg and in the pseudonormal
group is 146.11 mm Hg. Though the systolic BP values are higher in pseudonormal
group, it was not statistically significant (p=0.969).
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Correlation of diastolic BP with left ventricular diastolic dysfunction
Chart 6
As depicted in table 13  and chart 6  mean diastolic BP in the normal group is 85.44
mm Hg, in impaired relaxation group it is 88.57 mm Hg and in the pseudonormal
group is 90.32 mm Hg. Though the diastolic BP values are higher in pseudonormal
group, it was not statistically significant (p=0.809).
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Correlation of waist measurement - male with left ventricular
diastolic dysfunction
Chart 7
As depicted in table 13  and chart 7  mean waist measurement - male in the normal
group is 96.14 cms, in impaired relaxation group it is 95.32 cms and in the
pseudonormal group is 95.98 cms. Though the mean waist measurement - male values
are higher in normal group, it was not statistically significant (p=0.442).
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Correlation of waist measurement - female with left ventricular
diastolic dysfunction
Chart 8
As depicted in table 13   and chart 8 mean waist measurement - female in the normal
group is 95.00 cms, in impaired relaxation group it is 94.63 cms and in the
pseudonormal group is 94.11 cms. Though the mean waist measurement - female
values are higher in normal group, it was not statistically significant (p=0.454).
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Correlation of fasting blood sugar with left ventricular diastolic
dysfunction
Chart 9
As depicted in table 13   and chart 9  mean fasting blood sugar in the normal group is
113.14 mg/dl, in impaired relaxation group it is 128.36 mg/dl and in the
pseudonormal group is 131.75 mg/dl. Though the mean fasting blood sugar values are
higher in pseudonormal group, it was not statistically significant (p=0.300).
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Correlation of triglycerides with left ventricular diastolic dysfunction
Chart 10
As depicted in table  13 and chart 10  mean triglyceride in the normal group is 161.78
mg/dl, in impaired relaxation group it is 131.11 mg/dl and in the pseudonormal group
is 122.38 mg/dl. Though the mean triglyceride values are higher in normal group, it
was not statistically significant (p=0.220).
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Correlation of high density lipoproteins with left ventricular diastolic
dysfunction
Chart 11
As depicted in table 13   and chart 11   mean high density lipoprotein in the normal
group is 43.78 mg/dl, in impaired relaxation group it is 42.96 mg/dl and in the
pseudonormal group is 41.00 mg/dl. Though the mean high density lipoprotein values
are higher in normal group, it was not statistically significant (p=0.611).
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DISCUSSION
Left ventricular diastolic dysfunction may be the earliest marker of
metabolic syndrome induced heart disease, which leads to progressive
development of cardiac failure. Thus it is important to detect left
ventricular diastolic dysfunction at an early stage. This will prevent
progression of disease to failure.
Left ventricular diastolic dysfunction may also be caused by other
medical conditions. In our study the subjects with the above conditions,
which affect LVDD were excluded.
Previous studies like Tarumi et al (62)who reported LVDD 36% and
Antonio Nicolino A et al (63) reported LVDD from 32-40%. But in our
study we reported a prevalence of 52%. When compared to the above
mentioned studies, we had studied the pseudo normal pattern.
Hence the reason for high prevalence levels of LVDD in our study.
The recognition of pseudo normal pattern is important because it is an
intermediate stage impaired relaxation and restrictive filling which is a
more advanced stage of LVDD.
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In our study  mean age in the normal group is 46.96 years, in
impaired relaxation group it is 52.22 years and in the pseudonormal group
is 47.11 years.  The p value obtained was not statistically significant
(p=0.086).
Systolic and diastolic BP, waist measurement, FBS, TGL and HDL
levels did not correlate with LVDD and were not statistically significant.
Similar results were seen in Paul Poirier et al, N H Anderson et al and
Rajesh Rajput et al studies (64,65,66)
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SUMMARY AND CONCLUSION
 Left ventricular diastolic dysfunction was observed in 52% of total
subjects and 48% of total subjects have normal left ventricular
function. 36% impaired relaxation cases and 16% pseudo normal
cases contributed to th 52% prevalence of LVDD.
 Recognition of pseudonormal pattern of utmost importance. It is an
intermediary stage between mild impaired relaxation state and
advanced restrictive filling stage.
 LVDD had no correlation with blood pressure, fasting blood sugar,
waist measurement, triglycerides and high density lipoproteins
level.
 LVDD is the earliest manifestation of metabolic disease related
cardiomyopathy. Hence detecting it early  will prevent disease
progression to symptomatic cardiac failure and bring down the
disease burden.
 The clinical significance of the findings in terms of prognosis and
treatment needs to be determined.
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 This study is a hypothesis generating study.
 Hence results from our study needs to be reinvestigated using
robust research designs like cohort studies.
 Conventional echocardiography is a simple economical test for
detecting LVDD in metabolic syndrome patients who are
asymptomatic.
 ECHO diagnostic factors like E/A ratio, DT and IVRT should be
should be studied further and developed into accurate cost effective
screening tools for screening asymptomatic LVDD.
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LIMITATIONS OF THE STUDY
1. Low sample size
2. Selection bias while selecting subjects
3. Low financial support
4. Inability to use research design like cohort study due to  a lack
resources
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PROFORMA
Serial No :
Date :
Unit :
Name :
IP/0P No :
Age :
Sex :
Address :
Phone :
Education :
Occupation :
Income :
Social Class :
Past history :
HT
T2DM
Hypothyroidism
Heart disease
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EXAMINATION
Weight :
Height :
Waist circumference :
Pulse rate :
Blood pressure :
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INVESTIGATIONS
CBC:
HB
TC
DC
ESR
PLATELET COUNT
PCV
URINE ROUTINE
BLOOD SUGAR(R)
FBS
PPBS
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BLOOD UREA
SERUM CREATININE
ELECTROLYTES
Sodium
Potassium
Chloride
bicarbonate
SERUM URIC ACID
LIPID PROFILE
TOTAL CHOLESTEROL
HDL
TGL
LDL
VLDL
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THYROID FUNCTION TEST:
FREE T3
FREE T4
TSH
SERUM CORTISOL
USG ABDOMEN
ECG
ECHO
106
FOLLOW UP
BP:
FBS:
LIPID PROFILE:
TOTAL CHOLESTEROL
HDL
LDL
VLDL
TRIGLYCERIDES
ECHO:
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CONSENT FORM
1) i agree to participate in study titled a study on left ventricular diastolic
function assessed by echo in metabolic syndrome.
2)  i confirm that i have been told about this study in my mother tongue &
have had the oppurtunity to ask questions.
3) i understand that my partipation is voluntery & i may refuse to
participate at any time without giving any reason and  without affecting
my benefits.
4) i agree not  to restrict the use of any date or results  that arise from the
study
5) i agree to subject myself for echocardiogram  which is part of
management tool for my disease.
Name of the participant:
Sign/Thumb print
Investigator
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KEY WORDS
HT - Hypertension
DM - Diabetes mellitus
WC - Waist circumferance
ECHO - Echo cardiogram
DT - Decelaration time
IVRT - Isovolumetric relaxation time
SBP - Systolic blood pressure
DBP - Diastolic blood pressure
FBS - Fasting blood sugar
TGL - Triglycerides
TC - Total cholesterol
EF - Ejection fraction
LVH - left ventricular hypertrophy
S.NO NAME AGE SEXMale=1                  Female=2
SMOKING
No=0
Yes=1
PAST H/O HT
No=0     Yes=1
PAST H/O DM
No=0           Yes=1 WEIGHT(KG) WAIST CIR(CM) SBP DBP FBS TOAL CHO    TGL HDL LDL
ECG
Normal=1
Tachy=2
LVH=3
 EF% E (m/s) A(m/s) E/A DcT(ms) IVRT
1 CHINRAJ 55 1 1 1 0 76 98 130 90 122 198 220 47 11O 1 62 0.55 0.83 0.6626506 245 87
2 RANI 52 2 0 0 0 82 102 134 88 117 156 187 48 108 2 63 0.56 0.73 0.76712329 236 65
3 SAMPATH 44 1 1 1 0 72 92 130 90 114 185 157 44 98 1 66 0.67 0.98 0.68367347 247 90
4 MANIVEL 42 1 0 0 0 66 97 126 80 120 176 176 45 96 1 65 0.78 0.96 0.8125 228 121
5 KALYANI 36 2 0 0 0 70 96 130 80 118 156 167 44 88 1 62 0.68 0.87 0.7816092 241 87
6 SUBBARAO 39 1 1 0 1 73 92 142 88 128 178 167 46 93 3 65 0.56 0.98 0.57142857 256 105
7 PARVARHY 53 2 0 0 0 68 88 156 80 98 156 145 52 94 1 60 0.67 0.76 0.88157895 234 98
8 MALAKONDAIA 57 1 0 0 0 66 92 160 90 124 145 167 55 97 1 62 0.77 0.88 0.875 238 58
9 NIZAR 44 1 1 0 0 76 104 126 80 118 167 176 40 98 1 64 0.9 0.89 1.01123596 221 97
10 KANMANI 40 2 0 0 0 77 94 128 80 123 186 156 45 88 1 62 0.67 0.92 0.72826087 238 99
11 AZHAGAMMAL 49 2 0 0 1 78 93 146 94 98 198 156 55 110 3 66 0.55 0.78 0.70512821 249 88
12 VELU 42 1 1 0 0 72 88 138 80 123 187 152 38 98 1 62 0.67 0.88 0.76136364 248 98
13 KAMATCHI 54 2 0 0 0 75 90 136 90 129 178 145 50 102 1 64 0.76 0.78 0.97435897 230 98
14 CHELLASAMY 46 1 1 0 0 78 89 120 80 108 165 156 38 98 1 65 0.57 0.73 0.78082192 248 123
15 JEYALAKSHMI 37 2 0 0 0 81 93 120 82 98 174 152 40 89 1 65 0.67 0.78 0.85897436 237 112
16 MOH RIYAZ 42 1 0 0 0 88 87 134 88 90 176 143 43 92 1 65 0.68 0.89 0.76404494 256 105
17 SAGUNTHALA 43 2 0 0 0 72 84 140 82 108 149 176 52 87 1 64 0.68 0.98 0.69387755 254 108
18 RAJU 52 1 1 0 0 73 96 156 90 118 187 153 53 98 1 64 0.55 0.89 0.61797753 249 79
19 NATARAJAN 49 1 1 1 0 94 104 152 88 124 176 143 43 88 1 65 0.69 0.87 0.79310345 245 106
20 JOTHY 34 2 0 0 0 76 86 120 80 119 187 152 55 92 1 64 0.891 0.89 1.0011236 229 88
21 GANESAN 39 1 1 1 0 81 94 134 90 123 174 157 40 98 1 62 0.59 0.87 0.67816092 234 88
22 SELVARAJ 46 1 0 0 1 92 98 120 80 128 156 176 43 89 1 63 0.65 0.97 0.67010309 249 89
23 DHEEPA 38 2 0 0 0 84 94 128 84 98 156 162 43 92 1 65 0.56 0.87 0.64367816 256 105
24 TAMILARASI 42 2 0 0 0 79 93 132 84 116 176 158 40 97 1 64 0.57 0.78 0.73076923 245 99
25 BALAKRISHNAN 56 1 0 1 0 67 88 138 92 106 187 145 39 97 1 62 0.55 0.87 0.63218391 259 60
26 ELUMALAI 52 1 1 0 0 73 92 148 90 102 164 157 38 101 1 60 0.67 0.78 0.85897436 238 73
ECHO
27 KALA 41 2 0 0 1 82 86 128 84 123 176 154 55 102 1 65 0.58 0.78 0.74358974 243 108
28 RAJENDRAN 47 1 1 0 0 91 96 120 80 119 203 162 39 108 1 59 0.58 0.93 0.62365591 251 123
29 SUBBULAKSHMI 45 2 0 0 1 79 98 142 88 135 198 178 38 105 1 64 0.52 0.93 0.55913978 264 78
30 KALIMUTHU 38 1 1 0 0 72 95 120 84 120 176 178 40 98 1 65 0.45 0.98 0.45918367 265 88
31 PITCHAIMUTHU 53 1 0 0 0 80 96 148 90 98 168 167 44 97 1 67 0.55 0.78 0.70512821 238 76
32 MADHU 43 1 1 0 0 84 93 144 80 90 178 142 39 101 1 66 0.66 0.78 0.84615385 223 98
33 VALLI 49 2 0 0 0 76 98 126 90 99 186 154 55 101 1 67 0.55 0.78 0.70512821 229 87
34 FATHIMABEEBI 43 2 0 0 0 88 102 124 82 116 176 152 55 98 1 67 0.45 0.79 0.56962025 256 76
35 JOHN 50 1 1 0 0 78 98 128 90 118 165 154 40 96 1 66 0.47 0.96 0.48958333 260 69
36 GOWRI 48 2 0 0 0 68 92 138 92 119 198 178 40 98 1 65 0.51 0.89 0.57303371 248 79
37 CHELLAMMAL 56 2 0 0 0 76 98 134 90 102 169 156 52 108 1 64 0.67 0.79 0.84810127 226 67
38 MARIYAPPAN 45 1 1 0 0 78 99 120 82 118 187 167 45 109 1 67 0.67 0.87 0.77011494 238 99
39 RAGHU 41 1 1 0 0 82 104 130 80 102 224 157 54 119 1 66 0.8 0.87 0.91954023 221 77
40 ANSAR BASHA 58 1 1 0 0 86 105 120 80 112 204 157 45 98 1 66 0.67 0.87 0.77011494 246 109
41 GEETHA 57 2 0 0 1 92 106 138 90 111 198 149 42 98 1 65 0.67 0.94 0.71276596 248 123
42 SEETHALAKSHMI 53 2 0 0 0 75 93 128 84 119 178 178 55 89 1 65 0.56 0.89 0.62921348 256 107
43 SUBRAMANI 48 1 0 0 0 78 98 134 86 112 220 173 49 98 1 63 0.57 0.8 0.7125 247 106
44 CHINNATHAMBI 55 1 1 0 0 82 93 142 80 117 185 165 45 88 1 65 0.79 0.98 0.80612245 234 97
45 CHINNAMMMAL 52 2 0 1 0 76 94 138 88 116 178 154 45 92 1 65 0.58 0.98 0.59183673 256 87
46 RAJA 48 1 1 0 0 78 95 120 80 93 189 176 39 98 1 65 0.78 0.97 0.80412371 220 98
47 KANNIYAPPAN 55 1 1 0 0 82 103 130 80 115 209 157 55 109 1 65 0.79 0.78 1.01282051 212 58
48 JAMUNA 38 2 0 0 0 90 108 120 92 98 240 171 56 107 1 64 0.89 0.98 0.90816327 231 108
49 VELAMMAL 44 2 0 0 0 94 102 120 88 116 187 152 45 98 1 62 0.57 0.87 0.65517241 265 109
50 JEYACHANDRAN 58 1 0 1 0 91 106 138 92 119 167 157 40 109 1 63 0.45 0.87 0.51724138 256 57
